Nuwellis — Third Quarter 2026 Earnings Summary

Nuwellis reported a 24% year-over-year improvement in its third-quarter 2026 operating loss to $2.1 million, driven by a 430 basis point expansion in gross margin to 69.5% and a 13% reduction in operating expenses. Net sales for the quarter remained flat at $2.2 million due to a prior-year backorder comparison, though sales grew 12% sequentially and 13% for the first nine months to $6.6 million. The company sold 32 Aquadex consoles in the first nine months of 2026, an 88% increase from the prior period, while strengthening its balance sheet to $8.3 million in cash and cash equivalents. Strategic initiatives included an FDA 510(k) submission to expand Aquadex indications for pediatric patients and new distribution agreements for the AtriAmp and Zorro-Flow products.